Haemostasis and Vascular Disease in Dialysis Patients Receiving Erythropoietin Therapy

Raine A E G MacMahon S H Selwood N H Wing A J Brunner F. P. Mortality from myocardial infarction in patients on renal replacement therapy in the UK. Nephrol Dial Transplant 1991; 6: 902 (Abstract).

Carnot P. Sur le mécanisme de l'hyperglobulie provoquée par le sérum d'animaux en renovation sanguine. C R Soc Biol (Paris) 1906; 111: 344–46.

Erslev A. Humoral regulation of red cell production. Blood 1953; 8: 349–57.

Jacobsson B. Goldwasser L F Fried W. Plzak L. Role of the kidney in erythropoiesis. Nature 1957; 179: 633–34.

Erslev A J Caro J. Kansu E. Silver R. Renal and extrarenal erythropoietin production in anaemic rats. Br J Haematol 1980; 45: 65–72.

Goldwasser E. Kung C. K. Purification of erythropoietin. Proc Natl Acad Sci USA 1971; 68: 697–98.

Miyake T. Kung C K Goldwasser E. Purification of human erythropoietin. J Biol Chem 1977; 252: 5558–64.

Lin F K Suggs S. Lin C H . Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985; 82: 7580–84.

Jacobs K. Shoemaker C. Rudersdorf R. . Isolation and characterisation of genomic and cDNA clones of human erythropoietin. Nature 1985; 313: 806–10.

Winearls C G Oliver D O Pippard M J Reid C. Downing M R Coates P. M. Effects of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986; ii: 1175–78.

Casati S. Passerini P. Campise M R . Benefits and risks of protracted treatment with human recombinant erythropoietin in patients receiving haemodialysis. Br Med J 1987; 295: 1017–20.

Sundal E. Kaescr U. Correction of anaemia of chronic renal failure with recombinant human erythropoietin: Safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis-dependent patients. Nephrol Dial Transplant 1989; vmr-4: 979–87.

Sundal E. Businger J. Kappeler A. Treatment of transfusion-dependent anaemia of chronic renal failure with recombinant human erythropoietin. Nephrol Dial Transplant 1991; 6: 955–65.

Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Br Med J 1990; 300: 573–78.

Eschbach J W Abdulhadi M H Brown J K . Recombinant human erythropoietin in anaemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989; 111: 992–1000.

Cannella G. La Canna G. Sandrini M. . Renormalisation of high cardiac output and of left ventricular size following long-term recombinant human erythropoietin treatment of anaemic dialysed uraemic patients. Clin Nephrol 1990; 34: 272–78.

Abdulhadi M H Fouad-Tarazi F M Thomas J. Bravo E L Paganini E. P. The haemodynamic effects of correction of anaemia in haemodialysis patients using recombinant human erythropoietin. Nephrol Dial Transplant 1990; 5 (suppl 1): 102–108.

Tagawa H. Nagano M. Saito H. Umezu M. Yamakado M. Echocardiographic findings in haemodialysis patients treated with recombinant human erythropoietin: Proposal for a haematocrit most beneficial to haemodynamics. Clin Nephrol 1991; 35: 35–38.

Verbeelen D. Bossuyt A. Smitz J. Herman A. Dratwa M. Jonckheer M. H. Haemodynamics of patients with renal failure treated with recombinant human erythropoietin. Clin Nephrol 1989; 31: 6–11.

Macdougall I C Lewis N P Saunders M J . Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet 1990; 335: 489–93.

Roger S D Grasty M S Baker L R I Raine A. E. G. Effects of oxygen breathing and erythropoietin on hypoxic vasodilation in uraemic anaemia. Kidney Int 1992; 42: 975–80.

Schaefer R M Leschke M. Strauer B E Heidland A. Blood rheology and hypertension in haemodialysis patients treated with erythropoietin. Am J Nephrol 1988; 8: 449–53.

Brown C D Kieran M. Thomas L L Zhao Z-H Larsen R. Friedman E. A. Treatment of azotemic, nonoliguric, anaemic patients with human recombinant erythropoietin raises whole blood viscosity proportional to haematocrit. Nephron 1991; 59: 394–98.

Nonnast-Daniel B. Deschodt G. Brunkhorst R. . Long-term effects of treatment with recombinant human erythropoietin on haemodynamics and tissue oxygenation in patients with renal anaemia. Nephrol Dial Transplant 1990; 5: 444–48.

Lai K N Lui S F Leung J C K Lan E. Nicholls M. G. Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis. Nephron 1991; 57: 394–400.

Ono K. Hisasue Y. The rate of increase in hematocrit, humoral vasoactive substances and blood pressure changes in haemodialysis patients treated with recombinant human erythropoietin or blood transfusion. Clin Nephrol 1992; 37: 23–27.

Yaqoob M. Morris K. Bell G M Ahmad R. Suppression of renin–angiotensin–aldosterone axis with erythropoietin therapy by a negative feedback loop. Nephrol Dial Transplant 1992; 7: 125–28.

Martin J. Moncada S. Blood pressure, erythropoietin, and nitric oxide. Lancet 1988; i: 644 (Letter).

Vallance P. Benjamin N. Collier J. Erythropoietin, haemoglobin, and hypertensive crises. Lancet 1988; i: 1107 (Letter).

Ejerblad S. Ericsson J L E Eriksson I. Arterial lesions of the radial artery in uraemic patients. Acta Chir Scand 1979; 145: 415–28.

Gilchrest B A Rowe J W Mihm M. C. Clinical and histological skin changes in chronic renal failure: Evidence for a dialysis-resistant, transplant-responsive microangiopathy. Lancet 1980; ii: 1271–75.

London G M Marchais S J Safar M E . Aortic and large artery compliance in end-stage renal failure. Kidney Int 1990; 37: 137–42.

Goodnough L. Rudnick S. Price T. . Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy. N Engl J Med 1989; 321: 1163–68.

Edmunds M E Walls J. Tucker B. . Seizures in haemodialysis patients treated with recombinant human erythropoietin. Nephrol Dial Transplant 1989; vmr-4: 1065–69.

Van Geet C. Hauglustaine D. Verresen L. Vanrusselt M. Vermylen J. Haemostatic effects of recombinant human erythropoietin on chronic haemodialyais patients. Thromb Haemost 1989; 61: 117–21.

Macdougall I C Hallett Davies ME I. . Coagulation studies and fistual blood flow during erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant 1991; 6: 862–67.

Taylor J E Belch J J F McLaren M. Henderson I S Stewart W. K. Effect of erythropoietin therapy and erythropoietin withdrawal on blood coagulation and fibrinolysis in haemodialysis patients. Kidney Int 1993 (in press).

Taylor J E McLaren M. Henderson I S Belch J J F Stewart W. K. Prothrombotic effect of erythropoietin in dialysis patients detected by increased thrombinantithrombin III complex levels. Nephrol Dial Transplant 1992; 7: 235–39.

Heidenreich S. Rahn K-H Zidek W. Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int 1991; 39: 259–65.

Tepel M. Neusser M. Heidenreich S. Rahn K-H Zidek W. Erythropoietin induced hypertension is caused by direct vasopressor effects on renal resistance vessels and is mediated by increased cytosolic free calcium. Kidney Int 1992; 41: 492 (Abstract).

Van Geet C. Van Damme-Lombaerts R. Vanrusselt M. De Mol A. Proesmans W. Vermylen J. Recombinant human erythropoietin increases blood pressure, platelet aggregability and platelet free calcium mobilisation in uraemic children: A possible link. Thromb Haemost 1990; 64: 7–10.

Miller B. Scaduto R C Tilotson D L Botti J J Cheung J. T. Erythropoietin stimulates a rise in intracellular free calcium concentration in single early human erythroid precursors. J Clin Invest 1988; 82: 309–15.

Erne P. Bolli P. Burgisser E. Buhler F. Correlation of platelet calcium with blood pressure. N Engl J Med 1984; 310: 1084–88.

Benigni A. Livio M. Dodesini P. . Inhibition of human platelet aggregation by parathyroid hormone. Am J Nephrol 1985; 5: 243–47.

Raine A E G Roger S. D. Effects of erythropoietin on blood pressure. Am J Kidney Dis 1991; 18 (suppl 1): 76–83.

Bund S J Heagerty A. Edmunds M. Walls J. Erythropoietin does not induce vasoconstriction directly in human subcutaneous resistance arterioles. Nephron 1989; 53: 173 (Letter).

Anagnostou A. Lees E S Kessimian N. Levinson R. Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 1990; 87: 5978–82.

Berglund B. Ekblom B. Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy men. J Intern Med 1991; 229: 125–30.

Jamgotchian N. Krall J F Hu M S Abdella P. Lee D. B. N. An animal model for recombinant human erythropoietin (rHuEPO)-induced hypertension (HPT). Kidney Int 1990; 37: 387 (Abstract).

Celsing F. Svedenhag J. Pihlstedt P. Ekblom B. Effects of anaemia and stepwise-induced polycythaemia on aerobic power in individuals with high and low haemoglobin concentrations. Acta Physiol Scand 1987; 127: 47–57.

Williams B. Edmunds M E Thompson J P Burton R. Feehally J. Walls J. Does increasing haemoglobin concentration and haematocrit have a pressor effect in dialysis patients? Nephrol Dial Transplant 1989; vmr-4: 787–91.

Fleming L W Stewart W K Parrat D. Dextran antibodies, complement conversion and circulating immune complexes after intravenous iron dextran therapy in dialysed patients. Nephrol Dial Transplant 1992; 7: 35–39.

Raine A. E. G. Seizures and hypertension events. Semin Nephrol 1990; 10: 40–50.

Dessypris E N Gleaton J H Armstrong O. L. Effect of human recombinant erythropoietin on human marrow megakaryocyte colony formation in vitro. Br J Haematol 1987; 65: 265–69.

Johnson W J McCarthy J T Yanagihara T. . Effects of recombinant human erythropoietin on cerebral and cutaneous blood flow and on blood coagulability. Kidney Int 1990; 38: 919–24.

Gordge M P Leaker B. Patel A. Oviasu E. Cameron J S Neild G. H. Recombinant human erythropoietin shortens the uraemic bleeding time without causing intravascular haemostatic activation. Thromb Res 1990; 57: 171–82.

Huraib S. Al-Momen Ak Gader A M A Mitwalli A. Sulimani F. Abu-Aisha H. Effect of recombinant human erythropoietin (rHuEPO) on the hemostatic system in chronic haemodialysis patients. Clin Nephrol 1991; 36: 252–57.

Akizawa T. Kinrugasa E. Kitaoka T. Koshikawa S. Effects of recombinant human erythropoietin and correction of anaemia on platelet function in haemodialysis patients. Nephron 1991; 58: 400–406.

Cases A. Escolar G. Reverter J C . Recombinant human erythropoietin improves platelet function in uraemic patients. Kidney Int 1991; 42: 668–72.

Moia M. Mannucci P M Vizzotto L. Casati S. Cattaneo M. Ponticelli C. Improvment in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet 1987; ii: 1127–29.

Zwaginga J J Ijsseldijk M J W De Groot P G . Treatment of uremic anemia with recombinant erythropoietin also reduces the defects in platelet adhesion and aggregation caused by uremic plasma. Thromb Haemost 1991; 66: 638–47.

Taylor J E Henderson I S Stewart W K Belch J. J. F. Platelet aggregation in erythropoietin treated dialysis patients. Platelets 1992; 3: 47–52.

Taylor J E Mactier R A Henderson I S Belch J J F Stewart W. K. Dialysis efficiency in continuous ambulatory peritoneal dialysis patients treated with erythropoietin. Perit Dial Int 1992; 12: 221–26.

Schloesser L L Kipp M A Wenzel F. J. Thrombocytosis in iron-deficiency anaemia. J Lab Clin Med 1965; 66: 107–114.

Saniabadi A. Lowe G D O Madhok R. . Red blood cells mediate spontaneous aggregation of platelets in whole blood. Atherosclerosis 1987; 66: 175–80.

Trip M D Cats Manger V. Van Capelle F J L Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990; 322: 1549–54.

Taylor J E Henderson I S Stewart W K Belch J. J. F. Erythropoietin and spontaneous platelet aggregation in haemodialysis patients. Lancet 1991; 338 1361–62.

Taylor J E McLaren M. Mactier R A Henderson I S Stewart W K Belch J. J. F. The effect of dialyser geometry on platelet and granulocyte activation during haemodialysis with cuprophane membranes. Kidney Int 1992; 42: 442–47.

Saniabadi A R Lowe G D O Barbenel J C Forbes C. D. Further studies on the role of red blood cells in spontaneous platelet aggregation. Thromb Res 1985; 38: 225–32.

Saniabadi A R Tomiak R H H Lowe G D O Barbenel J C Forbes C. D. Dipyridamole inhibits red cell-induced platelet activation. Atherosclerosis 1989; 76: 149–54.

Turitto V T Weiss H. J. Red blood cells: Their dual role in thrombus formation. Science 1980; 207: 541–43.

Inauen W. Staubli M. Descoeudres C. Galeazzi R L Straub P. W. Erythrocyte deformability in dialysed and non-dialysed uraemic patients. Eur J Clin Invest 1982; 12: 173–76.

Hocken A G , Haemolysis in chronic renal failure. Nephron 1982; 32: 28–31.

Dreyling K W Steinhauer H B Geiger H. Platelet function under recombinant human erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant 1989; vmr-4: 472 (Abstract).

Turitto V T Weiss H J Baumgartner H. R. Platelet interaction with rabbit subendothelum in von Willebrand's disease: Altered thrombus formation distinct from defective platelet adhesion. J Clin Invest 1984; 74: 1730–41.

Belch J J F Zoma A A Richards I M McLaughlin K. Forbes C D Sturrock R. A. Vascular damage and factor-VIII-related antigen in the rheumatic diseases Rheumatol Int 1987; 7: 107–11.

Lowe G. D. O. Blood rheology in arterial disease. Clin Sci 1985; 68: 419–25.

Meade T W Vickers M V Thompson S G Stirling Y. Haines A P Miller G. J. Epidemiological characteristics of platelet aggregability. Br Med J 1985; 290: 428–32.

Koppensteiner R. Stockenhuber F. Jahn C. Balcke P. Minar E. Ehringer H. Changes in determinants of blood rheology during treatment with haemodialysis and recombinant human erythropoietin. Br Med J 1990; 300: 1626–27.

Letcher R L Chien S. Pickering T G Sealey J E Laragh J. H. Direct relationship between blood pressure and blood viscosity in normal and hypertensive subjects. Role of fibrinogen and concentration. Am J Med 1981; 70: 1195–202.

Dati F. Pelzer H. Barthels M. . Thrombin–antithrombin III complex (TAT): Multicentre evaluation of an enzyme immunoassay. Thromb Haemost 1989; 2: 165 (Abstract).

Brunkhorst R. Nonnast-Daniel B. Koch K M Frei U. Hypertension as a possible complication of recombinant human erythropoietin therapy. Contrib Nephrol 1991; 88: 118–25.

Gordge M P Leaker B R Rylance P B Neild G. H. Haemostatic activation and proteinuria as factors in the progression of chronic renal failure. Nephrol Dial Transplant 1991; 6: 21–26.

Nakamura Y. Chida Y. Tomura S. Enhanced coagulation–fibrinolysis in patients on regular haemodialysis treatment. Nephron 1991; 58: 201–204.

Green D. Stone N J Krumlovsky F. A. Putative atherogenic factors in patients with chronic renal failure. Prog Cardiovasc Dis 1983; 26: 133–44.

Steffen H M Brunner R. Muller R. . Peripheral haemodynamics, blood viscosity, and the renin-angiotensin system in haemodialysis patients under therapy with recombinant human erythropoietin. Contrib Nephrol 1989; 76: 292–98.

Macdougall I C Davies M E Hutton R D . The treatment of renal anaemia in CAPD patients with recombinant human erythropoietin. Nephrol Dial Transplant 1990; 5: 950–55.

Brunner R. Steffen H M Pollok M. . Blood rheology in haemodialysis patients treated with recombinant human erythropoietin. Contrib Nephrol 1989; 76: 306–14.

Meier W. Paulitschke M. Lerche D. Schmidt G. Zoellner K. Action of rHuEPO on mechanical membrane properties of red blood cells in children with end-stage renal disease. Nephrol Dialysis Transplant 1991; 6: 110–16.

Belch J. J. F. The role of the while blood cell in arterial disease. Blood Coagul Fibrinolysis 1990; 1: 183–92.

Bommer J. Kugel M. Schoeppe W. . Dose related effects of recombinant human erythropoietin on erythropoiesis. Contrib Nephrol 1988; 66: 85–93.

Taylor J E Bridges A. Henderson I S Stewart W K Belch J. J. F. Granulocyte aggregation in dialysis-dependent patients. Blood Coagul Fibrinolysis 1991; 2: 765–69.

Fernandez E. Betriu M A Montoliu J. Amoedo M L Mardaras J. Salamero P. Aspirin corrects the loss of dialysis efficiency after the increase in haematocrit induced by erythropoietin. Nephrol Dial Transplant 1991; 6: 822 (Abstract).